Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL
13. Februar 2018 01:15 ET
|
Momenta Pharmaceuticals, Inc.
--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of...
Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference
08. Februar 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast
07. Februar 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
30. Januar 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
-- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI)-- -- VAI status provides the potential for the near-term FDA approval of Sandoz’s Glatopa 40 mg ANDA-- ...
Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
05. Januar 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
03. Januar 2018 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., HERTFORDSHIRE, United Kingdom and PITTSBURGH, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL) today announced...
Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference
28. Dezember 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare Conference
08. November 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
01. November 2017 08:05 ET
|
Momenta Pharmaceuticals, Inc.
-- Ended third quarter with a strong cash position of $423M -- CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results...
Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
01. November 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.; Mylan N.V.
CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today...